Gómez-Matas Javier, Duran-Sanchon Saray, Lozano Juan-José, Ferrero Giulio, Tarallo Sonia, Pardini Barbara, Naccarati Alessio, Castells Antoni, Gironella Meritxell
Gastrointestinal & Pancreatic Oncology Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)/ Hospital Clínic Barcelona/ Fundació de Recerca Clínic Barcelona - Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
Bioinformatics Platform, CIBERehd, Barcelona, Catalonia, Spain.
iScience. 2024 Feb 20;27(3):109283. doi: 10.1016/j.isci.2024.109283. eCollection 2024 Mar 15.
Small nucleolar RNAs (snoRNAs) have been identified dysregulated in several pathologies, and these alterations can be detected in tissues and in circulation. The main aim of this study was to analyze the whole snoRNome in advanced colorectal neoplasms and to identify new potential non-invasive snoRNA-based biomarkers in fecal samples by different analytical approaches. SNORA51, SNORD15B, SNORA54, SNORD12B, SNORD12C, SNORD72, SNORD89, and several members of SNORD115 and SNORD116 clusters were consistently deregulated in both tissue sets. After technical validation, SNORA51 and SNORD15B were detected in FIT+ samples. SNORA51 was significantly upregulated in FIT+ samples from CRC patients compared to healthy controls. This upregulation, together with the fecal hemoglobin concentration, was sufficient to identify, among FIT+ individuals, patients with CRC (AUC = 0.86) and individuals with advanced adenomas (AUC = 0.68). These findings portray snoRNAs as an alternative source of candidates for further studies and SNORA51 appears as a potential non-invasive biomarker for CRC detection.
小核仁RNA（snoRNAs）已被发现在多种病理状态下存在失调，并且这些改变可以在组织和循环中检测到。本研究的主要目的是分析晚期结直肠肿瘤中的整个snoRNA组，并通过不同的分析方法在粪便样本中鉴定新的潜在非侵入性snoRNA生物标志物。SNORA51、SNORD15B、SNORA54、SNORD12B、SNORD12C、SNORD72、SNORD89以及SNORD115和SNORD116簇的几个成员在两组组织中均持续失调。经过技术验证，在粪便免疫化学检测（FIT）阳性样本中检测到了SNORA51和SNORD15B。与健康对照相比，CRC患者FIT阳性样本中的SNORA51显著上调。这种上调与粪便血红蛋白浓度一起，足以在FIT阳性个体中识别出CRC患者（曲线下面积[AUC]=0.86）和晚期腺瘤患者（AUC=0.68）。这些发现表明snoRNAs是进一步研究候选物的另一个来源，并且SNORA51似乎是用于CRC检测的潜在非侵入性生物标志物。
